Results 251 to 260 of about 1,579,650 (291)

CBFB-MYH11 directly activates TGFβ and PD-L1 to drive immune evasion in acute myeloid leukemia. [PDF]

open access: yesJ Immunother Cancer
Fang H   +18 more
europepmc   +1 more source

ANKRD49 promotes immune evasion in lung adenocarcinoma by activating the MEF2A/PD‑L1 axis. [PDF]

open access: yesBiol Direct
Sun TQ   +8 more
europepmc   +1 more source
Some of the next articles are maybe not open access.

Related searches:

The hidden side of PD-L1

Nature Cell Biology, 2020
PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.
Alison Jaccard, Ping-Chih Ho
openaire   +4 more sources

PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay

Current Drug Targets, 2020
Background: Immune checkpoint inhibitors targeting the programmed death receptor ligand 1 (PD-L1)/programmed death receptor 1 (PD-1) pathway represent a drastic change in the treatment landscape of RCC resulting in a dynamic and evolving scenario.
Cimadamore A.   +7 more
openaire   +4 more sources

Home - About - Disclaimer - Privacy